Thompson Davis & CO. Inc. Boosts Stock Position in GeneDx Holdings Corp. (NASDAQ:WGS)

Thompson Davis & CO. Inc. boosted its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 99.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,944 shares of the company’s stock after acquiring an additional 9,944 shares during the quarter. Thompson Davis & CO. Inc. owned 0.08% of GeneDx worth $55,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. HighTower Advisors LLC lifted its holdings in shares of GeneDx by 14.1% in the 3rd quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock worth $865,000 after buying an additional 29,361 shares during the period. Pathstone Family Office LLC lifted its holdings in shares of GeneDx by 262.2% in the 3rd quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock worth $198,000 after buying an additional 39,327 shares during the period. Trellus Management Company LLC lifted its holdings in shares of GeneDx by 55.0% in the 3rd quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock worth $564,000 after buying an additional 54,976 shares during the period. Finally, Oracle Investment Management Inc. lifted its holdings in shares of GeneDx by 14.9% in the 3rd quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock worth $3,620,000 after buying an additional 128,731 shares during the period. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on WGS. The Goldman Sachs Group upped their price objective on GeneDx to $11.00 and gave the stock a “neutral” rating in a research note on Monday, April 15th. TD Cowen upped their price objective on GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, BTIG Research upped their price objective on GeneDx from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday.

Insider Transactions at GeneDx

In related news, Director Casdin Capital, Llc bought 40,000 shares of the stock in a transaction dated Monday, March 4th. The shares were purchased at an average price of $8.74 per share, for a total transaction of $349,600.00. Following the completion of the purchase, the director now directly owns 2,702,609 shares of the company’s stock, valued at $23,620,802.66. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other GeneDx news, CEO Katherine Stueland sold 6,325 shares of the stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $11.04, for a total transaction of $69,828.00. Following the transaction, the chief executive officer now owns 75,869 shares in the company, valued at $837,593.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Casdin Capital, Llc purchased 40,000 shares of the stock in a transaction on Monday, March 4th. The shares were acquired at an average price of $8.74 per share, for a total transaction of $349,600.00. Following the transaction, the director now directly owns 2,702,609 shares of the company’s stock, valued at approximately $23,620,802.66. The disclosure for this purchase can be found here. Insiders have sold 21,249 shares of company stock worth $228,370 over the last quarter. 28.10% of the stock is currently owned by insiders.

GeneDx Stock Performance

Shares of WGS stock traded up $6.07 during mid-day trading on Tuesday, reaching $17.07. The stock had a trading volume of 7,282,556 shares, compared to its average volume of 325,185. The business’s fifty day moving average is $9.63 and its 200-day moving average is $5.19. The company has a current ratio of 3.10, a quick ratio of 2.95 and a debt-to-equity ratio of 0.23. The firm has a market cap of $444.67 million, a price-to-earnings ratio of -2.29 and a beta of 2.75. GeneDx Holdings Corp. has a 1-year low of $1.16 and a 1-year high of $18.24.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, February 20th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.01. The business had revenue of $57.42 million for the quarter, compared to analyst estimates of $57.00 million. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. On average, research analysts forecast that GeneDx Holdings Corp. will post -2.02 earnings per share for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.